Subject: Association of REVLIMID® (lenalidomide) with risk of second cancers
Celgene Inc., in consultation with Health Canada, has informed Canadian healthcare providers of important information related to the safety of REVLIMID® (lenalidomide) capsules.
Health Canada has authorized REVLIMID® for the treatment of patients with a condition called deletion 5q myelodysplastic syndrome (del 5q MDS) who require blood transfusions for anemia (low red blood cell counts). REVLIMID® is also authorized when used with dexamethasone to treat patients with multiple myeloma who have already had another treatment. Multiple myeloma is a cancer of plasma cells.
Celgene Inc. has worked with Health Canada to update the REVLIMID® Product Monograph with the following safety information:
• Second cancers such as skin cancers or other invasive solid tumors have been reported in a small number of patients with multiple myeloma.
• These cases have been reported in patients while taking REVLIMID® or after treatment with REVLIMID® is completed.
• Patients should talk to their healthcare professionals if they have any concerns about their own increased risk of having other cancers.
Read full details on the Health Canada website at: Health Canada Medical Advisories
No comments:
Post a Comment
TERMS OF USE
Those who post comments are accountable for the opinions they express, and the accuracy of the information they furnish. While we encourage writers to utilize this service on our site, we also strongly suggest they treat it as public forum where good taste counts. We reserve the right to decline for approval objectionable material from this site.
Writers that include profanity or personal attacks or other inappropriate comments - such as racist language, threats or comments unrelated to the story - will not be approved. Also, entries that are unsigned or signatures by someone other than the actual writer will not be approved.
While writers can still post anonymously, we strongly suggest that they do not do so.
Opinions, guidance and other information expressed in Omemee Pigeon eFlyer comments and by contributors to the Omemee Pigeon eFlyer, represent the individuals'; own views and are not necessarily those of the Omemee Pigeon eFlyer. The Omemee Pigeon eFlyer furnishes this type of forum and does not endorse and is not accountable for statements or advice from anyone other than an designated Omemee Pigeon eFlyer spokesperson.